Home » Newsletters » BioWorld Science

BioWorld Science

May 16, 2014

View Archived Issues

Results of a first-in-human phase I/II study with SA4Ag vaccine

Clinical trial tests the efficacy, safety and tolerability of selisistat

LassBio-1386 investigated for the treatment of PAH in a rat model

New ROR-gamma receptor modulators disclosed by Bristol-Myers Squibb and Exelixis

Ligand signs agreement with Omthera Pharmaceuticals for dyslipidemia-related diseases

TNF-alpha in saliva tested as a potential biomarker for carotid atherosclerosis

PATH to initiate phase III trial of oral rotavirus vaccine

INK-128 to be evaluated in glioblastoma patients undergoing surgery

Astex Pharmaceuticals joins Cancer Research UK's ECMC Combinations Alliance

Heron Therapeutics selects HTX-011 as lead candidate for post-surgical pain program

New IDH1/IDH2 inhibitors divulged by Agios Pharmaceuticals

Novel agents for HCV infection presented by Bristol-Myers Squibb

Researchers at Roche synthesize new mGlu5 receptor modulators

Retrophin provides access to RE-024 in pantothenate kinase-associated neurodegeneration

Portola Pharmaceuticals starts enrollment in phase III study of andexanet alfa and Xarelto

Senhwa Biosciences to begin phase I/II study of CX-4945 in cholangiocarcinoma

Phase II TT-401 trial begins in type 2 diabetes

MRC Technology and Daiichi Sankyo to identify novel targets for drug discovery

Ardelyx receives milestone payment for initiation of phase tenapanor trial

ZN-2007 as a novel HCV NS3 inhibitor with excellent in vivo activity and safety

Diffusion's phase I/II study of TSC for GBM reaches 1-year interim endpoint

Transgene's TG-6002 shows activity in mouse cancer models

Apricus to initiate phase IIa study of alprostadil cream in Raynaud's phenomenon

Nymox reports positive results from phase II trial of NX-1207 in prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...